LEIDEN, the Netherlands, Sept. 14, 2015 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR) today announced that PQ-010-002 is open for enrollment.
… trials, including the pivotal trial of sepofarsen for Leber congenital amaurosis 10. ProQR is implementing … for the treatment of severe genetic rare diseases such as Leber congenital amaurosis 10, Usher syndrome and autosomal …